Top Glove Corporation Bhd
Change company Symbol lookup
Select an option...
TGLVY Top Glove Corporation Bhd
ACQRU Independence Holdings Corp
KEGS 1812 Brewing Company Inc
PHUN Phunware Inc
WFC Wells Fargo & Co
XRX Xerox Holdings Corp
BIDU Baidu Inc
CDRO Codere Online Luxembourg SA
AMZN Amazon.com Inc
LYFT Lyft Inc
Go


Based in Malaysia
Company profile

Top Glove Corporation Bhd. is a Malaysia-based manufacturer of gloves. The Company's segments include Malaysia, Thailand and China. It offers a product range, which includes a non-glove segment comprising condoms, face masks, dental dams, exercise bands and household products, fulfilling demand in both the healthcare and non-healthcare segment. Its gloves product categories include medical, surgical procedure, food and services, cleanroom, and safety and industrial. Its non gloves product categories include medical care, personal care, oral care, home care and industrial care. The Company has manufacturing operations in Malaysia, Thailand, Vietnam and China. Its subsidiaries include Top Glove Sdn Bhd, Eastern Press Sdn Bhd, TG Healthcare Sdn Bhd, TG Medical (U.S.A.), Inc, TG Worldwide Sdn Bhd and Top Glove Engineering Sdn Bhd, among others.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$0.768
Day's Change
0.0225 (3.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.768
Day's Low
0.7326
Volume
(Heavy Day)

Today's volume of 1,226 shares is on pace to be much greater than TGLVY's 10-day average volume of 4,816 shares.

1,226

KRBP FINAL DEADLINE: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Application Deadline in Securities Class Action

11:32 am ET October 3, 2022 (Accesswire) Print

SAN FRANCISCO, CA / ACCESSWIRE / October 3, 2022 / Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ:KRBP) investors who purchased Kiromic shares to submit your losses now.

Class Period: June 25, 2021 - Aug. 13, 2021

Lead Plaintiff Deadline: Oct. 4, 2022

Visit:https://www.hbsslaw.com/investor-fraud/KRBP

Contact An Attorney Now:KRBP@hbsslaw.com

844-916-0895

Kiromic BioPharma, Inc. (KRBP) Securities Class Action:

The litigation focuses on Kiromic's statements about its development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1, allowing it to issue 8 million shares at $40 per share to investors, which secondary offering closed on or about July 1, 2021.

More specifically, Kiromic represented that it had applications to begin human clinical trials for the two new drug candidates, known as Investigational New Drug ("IND") applications, pending with FDA, and that the Company could commence clinical trials within 30 days of those IND applications unless the FDA imposed a clinical hold.

Unbeknownst to investors, the Company had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold.

On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received "comments" from the FDA on its two IND applications.

Then, on Aug. 13, 2021, the Company clarified that the FDA had put the INDs on "clinical hold."

After the class period, on Jan. 27, 2022, the Company's CEO abruptly departed.

These events have driven the price of Kiromic shares sharply lower.

"We're focused on investors' losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Kiromic and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Kiromic should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email KRBP@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP





View source version on accesswire.com:

https://www.accesswire.com/718523/KRBP-FINAL-DEADLINE-Hagens-Berman-National-Trial-Attorneys-Encourages-Kiromic-BioPharma-KRBP-Investors-with-Significant-Losses-to-Contact-Firms-Attorneys-Before-Oct-4th-Application-Deadline-in-Securities-Class-Action



comtex tracking

COMTEX_415815715/2457/2022-10-03T11:32:30

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.